The PIM Kinase Inhibitor TP-3654 in Combination with Ruxolitinib Exhibits Marked Improvement of Myelofibrosis in Murine Models

被引：1
|
作者：
Nath, Dipmoy [1 ]
Dutta, Avik [1 ]
Yang, Yue [1 ]
Whatcott, Clifford [2 ]
Warner, Steven L. [2 ]
Mohi, Golam [1 ]
机构：
[1] Univ Virginia, Biochem & Mol Genet, Charlottesville, VA USA
[2] Tolero Pharmaceut Inc, Lehi, UT USA
来源：
BLOOD | 2018年 / 132卷
关键词：
D O I：
10.1182/blood-2018-99-119421
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
54
引用
收藏
页数：2
相关论文
共 29 条
  • [21] Dynamic and Time-To-Event Analyses Demonstrate Marked Reduction in Transfusion Requirements for Janus Kinase Inhibitor-Naive Myelofibrosis Patients Treated with Momelotinib Compared Head to Head with Ruxolitinib
    McLornan, Donal
    Mesa, Ruben
    Catalano, John
    Cervantes, Francisco
    Devos, Timothy
    Egyed, Miklos
    Gotlib, Jason
    Kiladjian, Jean-Jacques
    Oh, Stephen
    Shimoda, Kazuya
    Coart, Elisabeth
    D'Hollander, Koenraad
    Donahue, Rafe
    Kowalski, Mark
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S329 - S330
  • [22] Dynamic and Time-to-Event Analyses Demonstrate Marked Reduction in Transfusion Requirements for Janus Kinase Inhibitor-Naive Myelofibrosis Patients Treated with Momelotinib Compared Head to Head with Ruxolitinib
    Mesa, Ruben A.
    Catalano, John
    Cervantes, Francisco
    Devos, Timothy
    Gotlib, Jason
    Kiladjian, Jean-Jacques
    McLornan, Donal P.
    Shimoda, Kazuya
    Coart, Elisabeth
    D'Hollander, Koenraad
    Donahue, Rafe
    Kowalski, Mark M.
    BLOOD, 2019, 134
  • [23] Dynamic and time-to-event analyses demonstrate marked reduction in transfusion requirements for janus kinase inhibitor-na_ive myelofibrosis patients treated with momelotinib compared head to head with ruxolitinib
    McLornan, D.
    Mesa, R.
    Catalano, J.
    Cervantes, F.
    Devos, T.
    Egyed, M.
    Gotlib, J.
    Kiladjian, J. -J.
    Shimoda, K.
    Coart, E.
    D'hollander, K.
    Donahue, R.
    Kowalski, M.
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 : 164 - 164
  • [24] Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor Treatment-Naive Patients with Myelofibrosis: Results of the MANIFEST-2 Randomized, Double-Blind, Phase 3 Study
    Rampal, Raajit K.
    Grosicki, Sebastian
    Chraniuk, Dominik
    Abruzzese, Elisabetta
    Bose, Prithviraj
    Gerds, Aaron T.
    Vannucchi, Alessandro M.
    Palandri, Francesca
    Lee, Sung-Eun
    Gupta, Vikas
    Lucchesi, Alessandro
    Oh, Stephen T.
    Kuykendall, Andrew T.
    Patriarca, Andrea
    Alvarez-Larran, Alberto
    Mesa, Ruben
    Kiladjian, Jean-Jacques
    Talpaz, Moshe
    Harris, Morgan
    Kays, Sarah-Katharina
    Jegg, Anna-Maria
    Li, Qing
    Brown, Barbara
    Harrison, Claire N.
    Mascarenhas, John
    BLOOD, 2023, 142
  • [25] Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignancies
    Koblish, Holly
    Li, Yun-Long
    Shin, Niu
    Hall, Leslie
    Wang, Qian
    Wang, Kathy
    Covington, Maryanne
    Marando, Cindy
    Bowman, Kevin
    Boer, Jason
    Burke, Krista
    Wynn, Richard
    Margulis, Alex
    Reuther, Gary W.
    Lambert, Que T.
    Roman, Valerie Dostalik
    Zhang, Ke
    Feng, Hao
    Xue, Chu-Biao
    Diamond, Sharon
    Hollis, Greg
    Yeleswaram, Swamy
    Yao, Wenqing
    Huber, Reid
    Vaddi, Kris
    Scherle, Peggy
    PLOS ONE, 2018, 13 (06):
  • [26] Improvement in Individual Symptoms and Total Symptom Score (TSS) and Matching-Adjusted Indirect Comparison (MAIC) Analysis to Compare TSS As a Continuous Endpoint in Patients with Myelofibrosis Treated with Pelabresib in Combination with Ruxolitinib Versus Janus Kinase Inhibitor Monotherapy
    Mesa, Ruben
    Kremyanskaya, Marina
    Patriarca, Andrea
    Gupta, Vikas
    Palandri, Francesca
    Devos, Timothy
    Harrison, Claire
    Rampal, Raajit K.
    Talpaz, Moshe
    Vannucchi, Alessandro
    Kuykendall, Andrew
    Kiladjian, Jean-Jacques
    Verstovsek, Srdan
    Colak, Gozde
    Dey, Debarshi
    Mascarenhas, John
    BLOOD, 2022, 140 : 11056 - 11059
  • [27] Allosteric MEK1/2 Inhibitor Refametinib (BAY 86-9766) in Combination with Sorafenib Exhibits Antitumor Activity in Preclinical Murine and Rat Models of Hepatocellular Carcinoma
    Schmieder, Roberta
    Puehler, Florian
    Neuhaus, Roland
    Kissel, Maria
    Adjei, Alex A.
    Miner, Jeffrey N.
    Mumberg, Dominik
    Ziegelbauer, Karl
    Scholz, Arne
    NEOPLASIA, 2013, 15 (10): : 1147 - 1157
  • [28] The Insulin-like Growth Factor I Receptor/Insulin Receptor Tyrosine Kinase Inhibitor PQIP Exhibits Enhanced Antitumor Effects in Combination with Chemotherapy Against Colorectal Cancer Models
    Flanigan, Sara A.
    Pitts, Todd M.
    Eckhardt, S. Gail
    Tentler, John J.
    Tan, Aik Choon
    Thorburn, Andrew
    Leong, Stephen
    CLINICAL CANCER RESEARCH, 2010, 16 (22) : 5436 - 5446
  • [29] TAS-116, an orally available HSP90a and 13 selective inhibitor, exhibits synergistic effects in combination with taxanes in EGFR-tyrosine kinase inhibitor-resistant human NSCLC xenograft models through the downregulation of key molecules involved in drug resistance of cancer chemotherapy.
    Muraoka, Hiromi
    Kanoh, Akira
    Hashimoto, Akihiro
    Ito, Kenjiro
    Suzuki, Takamasa
    Takahashi, Kouichi
    Yoshimura, Chihoko
    Kitade, Makoto
    Yonekura, Kazuhiko
    Ohkubo, Shuichi
    Utsugi, Teruhiro
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
123